Opendata, web and dolomites

StaphIMPACT SIGNED

SA.100: Next-generation targeted antibacterial product entering European market

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 StaphIMPACT project word cloud

Explore the words cloud of the StaphIMPACT project. It provides you a very rough idea of what is the project "StaphIMPACT" about.

driving    claiming    produces    ip    communication    develops    100    syndrome    health    dermatology    compounds    8b    deaths    skin    mrsa    hyper    roll    final    facilities    small    unless    helping    kols    brand    extra    full    employment    infections    2050    cosmetics    million    threats    humanity    market    alternatives    smei    staphylococcus    pharma    rosacea    first    owns    biggest    inflammatory    expressed    2024    endolysin    resistance    netherlands    caused    eczema    regardless    2018    launched    company    acne    changing    cancer    aureus    stakeholders    2023    antibiotic    diabetic    antibiotics    license    us       people    wound    according    companies    ideas    trillion    secured    ige    life    10    suffering    thousands    chosen    177b    markets    triggered    indications    care    resistant    soft    replace    gladskin    cagr    kills    19    clinical    kill    world    micreos    aggravated       innovation    sa    capacity    antibacterial    profitability    prepares    contribution    bacteria    time   

Project "StaphIMPACT" data sheet

The following table provides information about the project.

Coordinator
MICREOS HUMAN HEALTH BV 

Organization address
address: BANKAPLEIN 2
city: S GRAVENHAGE
postcode: 2585EV
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 3˙565˙625 €
 EC max contribution 2˙495˙937 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MICREOS HUMAN HEALTH BV NL (S GRAVENHAGE) coordinator 2˙495˙937.00

Map

 Project objective

According to the WHO, antibiotic resistance is one of humanity’s biggest health threats, claiming ~10 million extra deaths per year and US$100 trillion by 2050, unless alternatives to antibiotics are developed. Micreos has developed the world’s first targeted antibacterial products, set to replace antibiotics. With its endolysin technology, for the first time it is possible to kill only the unwanted bacteria, regardless of resistance. Micreos’ endolysin technology was chosen as Europe’s most relevant Innovation 2018 (Ideas from Europe). Its first lead endolysin, SA.100, kills only Staphylococcus aureus, including the resistant MRSA. Soft-launched under the Gladskin brand in the Netherlands, it’s having life-changing impact for thousands of people with inflammatory skin conditions caused or aggravated by S. aureus, including eczema, acne, rosacea and Hyper IgE syndrome. Micreos also develops products for diabetic wound infections and a skin cancer triggered by S. aureus. Micreos owns all relevant IP and know-how on its technology and produces its compounds and Gladskin products at small-scale at its facilities in the Netherlands. With this SMEi, Micreos prepares for full roll-out into the EU markets of its SA.100/Gladskin. This includes scale-up of production capacity, strengthening clinical evidence and communication of results to KOLs and relevant stakeholders. Leading pharma and cosmetics companies have expressed interest to in-license Micreos’ technology for particular indications. Relevant markets are the consumer’s skin care market ($177b by 2024; CAGR 4.7%) and dermatology market ($19.8b by 2023; CAGR 9.1%.). Own contribution by Micreos for this SMEi is already secured. This SMEi enables Micreos to take final steps for EU-wide roll-out, driving employment growth and company profitability, and helping people suffering from inflammatory skin conditions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STAPHIMPACT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STAPHIMPACT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

Presque (2019)

Smart Nursing Bra

Read More